⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25176207 | 0.72 | ALDH1A1 (0.32) | — | |
| SCHEMBL5739397 | 0.72 | DRD2 (0.35) | — | |
| SCHEMBL7485887 | 0.70 | HTR1A (0.30) | — | |
| SCHEMBL3318107 | 0.69 | — | — | |
| SCHEMBL1034571 | 0.67 | TSHR (0.31) | — | |
| SCHEMBL972409 | 0.67 | — | — | |
| SCHEMBL3322658 | 0.66 | ALDH1A1 (0.35) | — | |
| SCHEMBL14979977 | 0.65 | LMNA (0.33) | — | |
| SCHEMBL6512444 | 0.65 | — | — | |
| SCHEMBL3432647 | 0.65 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022029795-A1 | An environment friendly process for the preparation of Lapatinib Ditosylate of Formula 1(b) | SUMAR BIOTECH LLP (IN) | 2022-02-10 | — | — | WO | disclosed |
| US-20150366868-A1 | CANCER TREATMENT METHOD | NOVARTIS AG (CH) | 2015-12-24 | — | — | US | disclosed |
| WO-2014170910-A1 | PROCESS FOR THE PREPARATION OF LAPATINIB | NATCO PHARMA LIMITED (IN) | 2014-10-23 | — | — | WO | disclosed |
| WO-2014059956-A1 | A METHOD OF PRODUCING THE KEY INTERMEDIATE OF LAPATINIB SYNTHESIS | ZENTIVA, K.S. (CZ) | 2014-04-24 | — | — | WO | disclosed |
| US-8664389-B2 | Process for the preparation of lapatinib and it's pharmaceutically acceptable salts | NATCO PHARMA LIMITED (IN) | 2014-03-04 | — | — | US | disclosed |
| US-8444988-B2 | Cancer treatment method | GLAXOSMITHKLINE LLC (US) | 2013-05-21 | — | — | US | disclosed |
| US-20120245351-A1 | PROCESS FOR THE PREPARATION OF LAPATINIB AND ITS PHARMACEUTICALLY ACCEPTABLE SALTS | NATCO PHARMA LIMITED (IN) | 2012-09-27 | — | — | US | disclosed |
| US-20120058113-A1 | CANCER TREATMENT METHOD | NOVARTIS AG (CH) | 2012-03-08 | — | — | US | disclosed |
| US-20110312982-A1 | Cancer Treatment Method | NOVARTIS AG (CH) | 2011-12-22 | — | — | US | disclosed |
| US-20110263852-A1 | NOVEL PROCESS FOR THE PREPARATION OF LAPATINIB AND ITS PHARMACEUTICALLY ACCEPTABLE SALTS | NATCO PHARMA LIMITED (IN) | 2011-10-27 | — | — | US | disclosed |
| EP-1353693-B1 | PHARMACEUTICAL COMBINATION CONTAINING A 4-QUINAZOLINEAMINE AND PACLITAXEL, CARBOPLATIN OR VINORELBINE FOR THE TREATMENT OF CANCER | GLAXO GROUP LTD (GB) | 2005-03-16 | — | — | EP | disclosed |
| EP-1512413-A2 | Pharmaceutical combination containing a 4-quinazolineamine and another anti-neoplastic agent for the treatment of cancer | GLAXO GROUP LIMITED (GB) | 2005-03-09 | — | — | EP | disclosed |
| EP-1488809-A1 | Pharmaceutical combination containing a 4-quinazolineamine and another anti-neoplastic agent for the treatment of cancer | GLAXO GROUP LIMITED (GB) | 2004-12-22 | — | — | EP | disclosed |
| US-20040053946-A1 | Cancer treatment method | NOVARTIS AG (CH) | 2004-03-18 | — | — | US | disclosed |
| EP-1353693-A2 | PHARMACEUTICAL COMBINATION CONTAINING A 4-QUINAZOLINEAMINE AND ANOTHER ANTI-NEOPLASTIC AGENT FOR THE TREATMENT OF CANCER | GLAXO GROUP LIMITED (GB) | 2003-10-22 | — | — | EP | disclosed |
| WO-2002056912-A2 | PHARMACEUTICAL COMBINATION FOR THE TREATMENT OF CANCER CONTAINING A 4-QUINAZOLINEAMINE AND ANOTHER ANTI-NEOPLASTIC AGENT | GLAXO GROUP LIMITED (GB) | 2002-07-25 | — | — | WO | disclosed |
| EP-1192151-A1 | ANILINOQUINAZOLINES AS PROTEIN TYROSINE KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2002-04-03 | — | — | EP | disclosed |
| WO-2001004111-A1 | ANILINOQUINAZOLINES AS PROTEIN TYROSINE KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2001-01-18 | — | — | WO | disclosed |
| EP-0912559-A1 | FUSED HETEROCYCLIC COMPOUNDS AS PROTEIN TYROSINE KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 1999-05-06 | — | — | EP | disclosed |
| WO-1998002434-A1 | FUSED HETEROCYCLIC COMPOUNDS AS PROTEIN TYROSINE KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 1998-01-22 | — | — | WO | disclosed |